Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with...

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hyperkalemia poses a significant management challenge in patients with co-existing heart failure (HF) and chronic kidney disease (CKD).
• Renin-angiotensin-aldosterone system (RAAS) inhibitors are crucial for managing HF and CKD but are often limited by hyperkalemia.
• Mineralocorticoid receptor antagonists (MRAs) are vital RAAS inhibitors, but their use is frequently restricted by hyperkalemia.

Observation:

• An 88-year-old woman with hypertensive heart failure and chronic kidney disease presented with persistent hyperkalemia.
• This patient's high potassium levels complicated the administration of essential MRAs.

Findings:

• Concomitant administration of sodium zirconium cyclosilicate (SZC) allowed for the safe use of an MRA.
• SZC, a non-absorbed zirconium silicate, effectively manages hyperkalemia by exchanging ions in the GI tract.
• The patient tolerated MRA therapy without exacerbation of hyperkalemia due to SZC.

Implications:

• Sodium zirconium cyclosilicate may represent a valuable therapeutic option for managing hyperkalemia in HF and CKD patients.
• SZC could facilitate the safe and effective use of MRAs in a challenging patient population.
• This approach may improve cardiovascular and renal outcomes by enabling guideline-directed medical therapy.